AREV Brands International Ltd. Announces Asset Purchase Agreement Completed to Bare Topicals from Alternative Extracts Inc.
Momentum Public Relations
Press Release: November 9, 2018
AREV Brands International Ltd. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce it has completed the asset purchase (the “Acquisition Agreement”) dated November 9, 2018 with Alternative Extracts Inc. (“AEI”). To acquire 100% of the Bare Topicals assets in consideration for issuance of 500,000 common shares of the Company at a deemed price of $0.32 per share issued by the Company, for an aggregate value of $160,000.
Bare Brands is a Line of Award Winning Cannabis Infused Topical Products aim to provides safe alternatives to achieving significant pain relief and treatment of skin conditions.
2016
Bio Cup – 1st place topical (Magik)
Bio Cup – 2nd Place topical (SPF 420)
Bio Cup – 1st place topical people’s choice (Magik)
Bio Cup – 2nd Place topical people’s choice (SPF 420)
Bio Cup – 2nd Place best product (overall for the event) (SPF 420)
Karma Cup – 3rd place topical (Magik)
2017
Okanagan Cannabis Cup – 2nd place topical (Magik)
High Times Cannabis Cup – 2nd Place topical (Magik)
Karma Cup – 1st place topical (Recover)
Karma Cup – 3rd place topical (Magik)
2018
The Canna Cup – 1st place topical
The Grey Area Festival – 2nd Place topical (Releaf)
Okanagan Cannabis Cup – 2nd Place topical (Recover)
Karma Cup – 2nd Place topical (Recover)
The most awarded topical company in Canada.
Mike Withrow, CEO for AREV Brands International states “This acquisition is another that adds to the portfolio of products AREV continues to assemble while working on obtaining ACMPR Licencing to sell any of our cannabis based products. In the meantime we are preparing the Bare Topicals herbal line for production.”
The Company, effective immediately, has issued 500,000 stock options to Directors, Officers and Consultants of the Company at a price of $0.41 for a period of 5 years from the issuance date. These options will vest immediately.
Seek safe harbor and forward-looking statements.
For further information, contact Mike Withrow, mike.withrow.vn@gmail.com.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Brands International Ltd.
AREV Brands International Ltd. (“AREV”) produces and delivers functional compounds and ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of terpenes, cannabinoids and flavonoids. These premium ingredients and formulations are used in products targeted for sale in the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV innovates through extraction to produce extracts from specific selected plant and exude from trees that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
- Published in AREV Nutrition Sciences, Business, Life Sciences, Medical Marijuana, News Home, Technology
CROP Working ‘Rapidly’ To Vertically Integrate California Production, Extraction, Distribution And Retail
Momentum Public Relations
Press Release: November 7, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that it is working towards complete vertical integration in California. Processing continues at Humboldt Farm and new automation equipment has arrived to increase efficiencies and continually increase return on investment (ROI) of finished inventory.
Additionally, CROP’s Emerald Heights retail brand has just completed the stage three interview process with the City of San Bernardino which is a major hurdle before the final licensing review to open its first California retail location. CROP is currently going through the process of opening two Emerald Heights locations in Italy, one in Nevada and one at the aforementioned location in California.
The company’s tenant is currently accepting and reviewing bids from distributors to represent the company’s production under its Hempire, Evolution and White Rhino brands. The tenant has also applied for its own distribution license to represent its own production and the production of other complimentary producers in the region which will result in another license in the growing portfolio of tenant licensees.
CROP has also been notified that the tenants are preparing an extraction license application for Humboldt Farm which will maximize the ROI and broaden the range of Stock Keeping Units (‘SKUs’) available to retail locations.
CROP has submitted its building plans to the Humboldt County Building and Planning Department to increase the production of the California facility at a cost of $1,000,000 of which $250,000 has already been spent. The increased production will result in an additional ~12,000 pounds of high-quality cannabis and 3,000 pounds of secondary material per year.
CROP Infrastructure CEO, Michael Yorke, stated: “The significance of fully vertically integrating cannot be understated and we are working towards that end as rapidly as is practicable. As with CROP’s worldwide tenant strategy, production is always focused on high quality at low cost. With extraction and retail verticals now in process, the opportunity to maximize ROI on a significant scale presents the opportunity to control CROP’s tenant destiny and maximize future profits.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, an 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
CROP Completes 2018 Harvest at Nevada CBD Farm and Prepares First Shipment
Momentum Public Relations
Press Release: November 6, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announces an update on its 1,865-acre hemp-CBD farm.
CROP’s tenant has now completed the harvest of 240 acres of CBD hemp. Samples have been sent out for independent testing to determine CBD concentrations and for a Certificate of Analysis (‘COA’). Once the COA has been received, the CBD will be shipped to the company’s partnertoll processor to produce CBD isolate, as announced October 10, 2018. The company has also completed site testing at the entire Hemp-CBD project and soil is ready for 2019 planting. The company is developing lines of CBD capsule and tinctures to maximize its returns from its CBD production. The hemp & CBD isolate, and related products will be sold under the company’s Hempire and Tiff CBD brands and utilized for the Canna Drink beverage line.
Furthermore, the company’s tenant is now accepting inquiries for bulk orders of CBD isolate from the 2018 production.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, an 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in CROP Infrastructure, Marijuana, Medical Marijuana, News Home
Tetra Bio-Pharma Enters into Non-Binding Proposal to Acquire Panag Pharma Inc.
Momentum Public Relations
Press Release: November 6, 2018
The Proposed Transaction is expected to provide Tetra:
- With the most robust Pharmaceutical and Natural Health Products (NHP) pipeline of any Cannabinoid company;
- With more pharmaceutical and natural health products;
- The ability to sell these products worldwide; and
- Access to Panag’s NHP portfolio which is not included in the present in-licensing agreement with Panag.
Tetra Bio-Pharma Inc., (“Tetra” or the “Company“), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced it has entered into a non-binding proposal (the “Proposal“) with the shareholders (the “Vendors“) of Panag Pharma Inc. (“Panag“) for the acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the “Proposed Transaction“). Panag is a Canadian-based life sciences company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain. Their significant formulation expertise in the wellness market will allow Tetra to expand its commercial operations.
Dr. Guy Chamberland, CEO and CSO of Tetra stated, “We are very pleased to announce this news to our shareholders. We have been working with Panag for over a year and as a combined entity we will have a robust product pipeline of cannabinoid derived drugs for development as prescription or OTC drugs. Tetra is not just acquiring assets and intellectual property, we are joining a group of world-renowned cannabinoid experts that will help take Tetra to the next level as a pharmaceutical company.”
Panag will remain a separate subsidiary owned 100% by Tetra and will provide Tetra with additional discovery and early phase drug development capacity. With this robust product pipeline, Tetra intends to continue to implement its out-licensing program to generate additional revenues via upfront payments, milestone payments, and royalties and actively pursue the clinical development of lead products.
“Panag will bring Tetra Natural Health a unique pipeline of products, thereby strengthening our role as a key player in the cannabinoid wellness market,” said Richard Giguere, CEO of Tetra Natural Health. “We look forward to working with Panag to commercialize these products globally and expect to generate revenues from these products by Q4 2019 following completion of the acquisition.”
According to Dr. Orlando Hung, a co-founder of Panag, “We are very excited to have the opportunity to continue our decades of cannabinoid research work and partner for commercialization with Tetra Bio-Pharma. The timing is perfect as there is an urgent need for non-opioid medications to treat pain and inflammation. We expect the Panag-Tetra Bio-Pharma combined portfolio of cannabinoid products to play a significant role in the management of pain and inflammation. We are particularly pleased to have the support of Tetra Bio-Pharma to advance the development and research of Panag cannabinoid products.”
Pursuant to the Proposal, Tetra would acquire 100% of the issued and outstanding shares of Panag for an aggregate consideration of $12,000,000, on a debt-free basis and subject to customary post-closing adjustments. The purchase price would be payable by Tetra delivering to the Vendors, on the closing date of the Proposed Transaction, (i) $3,000,000 in cash and (ii) $9,000,000 payable in common shares of Tetra. The Proposal also contemplates the payment by Tetra to the Vendors of an aggregate amount of up to $15,000,000 in cash in milestone payments upon the achievement of operational targets associated with marketing approvals and commercialization of both human and veterinary drug products by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The milestone payments would be accelerated in the event of a bankruptcy, insolvency, change of control or sale of all of the assets of Tetra.
Two of the Vendors, Bill Cheliak and Gregory Drohan, are non-arm’s length parties to Tetra within the meaning of the rules of the TSX Venture Exchange. Mr. Cheliak is the Chairman of the Board of Directors of the Company and Mr. Drohan is a Director of the Company. The Proposed Transaction will not result in the issuance of securities to non-arm’s length parties as a group as payment of the purchase price exceeding 10% of the number of outstanding shares of the Company on a non-diluted basis.
The Company expects that the Proposed Transaction will be completed by the end of the 2018 calendar year. 100% of the shareholders of Panag have signed the term sheet. Completion of the Proposed Transaction remains subject to a number of conditions, including the completion of a satisfactory due diligence investigation by Tetra, the negotiation of a definitive purchase agreement, the approval by Panag’s shareholders in accordance with the shareholders’ agreement of Panag, the receipt of all required regulatory approvals, including that of the TSX Venture Exchange and such other closing conditions as are customary in transactions of this nature. There can be no assurance that such conditions will be satisfied and that the Proposed Transaction will be completed as described or at all.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Panag Pharma:
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.
Source: Tetra Bio-Pharma
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001
Momentum Public Relations
Press Release: November 1, 2018
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain. It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia. The study is expected to begin and end in Q4 2018.
“We are pleased to announce this critical Phase 1 trial focused on the PK and safety of our PPP001 pellet delivered by vaporization,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “Over the last 3 months we have analyzed the composition of the vapor. This data combined with the results of this Phase 1 will provide the critical pharmacological information required by physicians to adequately guide future efficacy studies in patients who suffer from a chronic condition such as fibromyalgia where there are limited treatment options and there is a large unmet medical need. It may also provide an alternative mode of delivery for those patients who prefer not to smoke.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
CROP Developing One Ton Nevada Extraction Facility With 60% Payment Coming From 1,500,000 Pound Supply Agreement
Momentum Public Relations
Press Release: November 1, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that the company has now engaged an ISO/GMP rated extraction facility developer to build a one ton per day extraction facility at its Nevada farm.
On October 23rd CROP announced a 500,000 pound annual (1,500,000 over 3 years) supply agreement with a commercial extraction technology company. The same company will be developing, and providing, extraction equipment for the CROP Nevada extraction facility. The initial $3.2 Million, equivalent to ~89,000 pounds of product, will be allocated towards paying for 60% of the extraction facility. The balance of ~$2.0 Million, due in cash over the next eight months will be financed by revenue from the company’s operations.
As previously announced, the CBD flower off take is to be delivered in shipments of 50,000 dry pounds on a bi-monthly basis with payment to be made plus the cost of delivery of $36.00 per pound to $57.00 per pound depending on Certificate of Analysis of the CBD content with deliveries starting August 2019.
Cannabis industry analysts, The Brightfield Group, estimate the hemp-CBD market alone could reach $22-billion by 2022.
CROP is in process of harvesting its 240 acres planted this year, which will be processed for isolate and is also readying its 1,865-acre CBD farm for 2019 planting.
CROP CEO, Michael Yorke, stated: “The synergies and relationship between CROP and our off-take partner continue to evolve. We look forward to continuing to develop this new partnership into new opportunities and other territories. We believe this is an effective and creative way of financing and developing our growth in a non-dilutive arrangement.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, a 1,865-acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
Tetra Natural Health Signs Exclusive Agreement for the Distribution of their Hemp Energy Drink in Canada and the USA
Momentum Public Relations
Press Release: November 1, 2018
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.
“We are thrilled in having signed this agreement with Kombucha Baby and its distribution partners providing Tetra Natural Health with access to a significant number of retail outlets in both Canada and the USA,” stated Richard Giguere, CEO of Tetra Natural Health.
“We are very excited to be adding the Hemp Energy Drink to our portfolio of products that will be available to our existing and potential client base,” stated Dan McKenna, President and CEO of Kombucha Baby Brewing Company Inc. “Numerous Canadian and U.S. customers representing thousands of retail outlets have indicated a strong interest in carrying this unique Natural Health Product (NHP).”
AboutTetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
CROP Announces Addition of Former Coca-Cola Branding Exec Arashdeep Singh to Head Up CannaDrink Line
Momentum Public Relations
Press Release: October 31, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it has signed former Coca-Cola branding executive Arashdeep Singh to lead the CannaDrink beverage line.
Singh has nearly a decade of experience with The Coca-Cola Company, including his last position as a Senior Brand Manager for a C$750.0 million portfolio of Coca Cola trademark products. His experience includes a varied mix of marketing disciplines and is a specialist in brand marketing and new product launches.
Over the years with Coca-Cola, Singh:
- Drove integrated brand campaigns to add new consumers and drive consumption frequency, using a combination of digital and traditional media.
- Built a new consumption occasion using a strong festival campaign for deeper household penetration.
- Led the creative agencies to conceptualize and execute integrated brand campaigns and build key brand imagery statements.
- Helped launch Coca-Cola Zero in the markets of Bhutan & Sri Lanka to develop the Diets & Lights category.
- Recruited new consumers by inducing more trials for the brand using experiential sampling. Added to key brand pillars of Brand Preference and Brand Love Score.
- Partnered with the National Customers and Emerging channels to drive volume growth
Standardized the E-Commerce presence with new layouts from a commissioned research to drive click-through rates. - Contributed to household penetration using innovative point of sale interventions in Modern trade. Arrested decline in Cinemas using co-branded incidence drivers with key customers.
CROP CEO, Michael Yorke, stated: “Someone of Arash’s caliber joining us is a big boost for our management team. As a growing organization our executive branch often wears many hats so having a specialist like Arash to head up this important pillar of CROP’s growth is exciting for myself and the entire CROP family.”
Arashdeep Singh, Head of Marketing at CannaDrink said, “For years, the benefits of cannabidiol have languished under a false stigma. With a welcome expansion of legalization, CannaDrink is committed to bring these products to the new age consumers. I am truly excited to be a part of this evolutionary journey.”
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
CROP Announces Addition of Former Coca-Cola Branding Exec Arashdeep Singh to Head Up CannaDrink Line
Momentum Public Relations
Press Release: October 31, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it has signed former Coca-Cola branding executive Arashdeep Singh to lead the CannaDrink beverage line.
Singh has nearly a decade of experience with The Coca-Cola Company, including his last position as a Senior Brand Manager for a C$750.0 million portfolio of Coca Cola trademark products. His experience includes a varied mix of marketing disciplines and is a specialist in brand marketing and new product launches.
Over the years with Coca-Cola, Singh:
- Drove integrated brand campaigns to add new consumers and drive consumption frequency, using a combination of digital and traditional media.
- Built a new consumption occasion using a strong festival campaign for deeper household penetration.
- Led the creative agencies to conceptualize and execute integrated brand campaigns and build key brand imagery statements.
- Helped launch Coca-Cola Zero in the markets of Bhutan & Sri Lanka to develop the Diets & Lights category.
- Recruited new consumers by inducing more trials for the brand using experiential sampling. Added to key brand pillars of Brand Preference and Brand Love Score.
- Partnered with the National Customers and Emerging channels to drive volume growth
Standardized the E-Commerce presence with new layouts from a commissioned research to drive click-through rates. - Contributed to household penetration using innovative point of sale interventions in Modern trade. Arrested decline in Cinemas using co-branded incidence drivers with key customers.
CROP CEO, Michael Yorke, stated: “Someone of Arash’s caliber joining us is a big boost for our management team. As a growing organization our executive branch often wears many hats so having a specialist like Arash to head up this important pillar of CROP’s growth is exciting for myself and the entire CROP family.”
Arashdeep Singh, Head of Marketing at CannaDrink said, “For years, the benefits of cannabidiol have languished under a false stigma. With a welcome expansion of legalization, CannaDrink is committed to bring these products to the new age consumers. I am truly excited to be a part of this evolutionary journey.”
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home